key: cord-1004717-0adcuaqz authors: Finsterer, Josef; Scorza, Fulvio A title: Clinical and Pathophysiologic Spectrum of Neuro-COVID date: 2021-04-08 journal: Mol Neurobiol DOI: 10.1007/s12035-021-02383-0 sha: ff80b77c6b4c98a24da038e3e506b9d2eb4e3b16 doc_id: 1004717 cord_uid: 0adcuaqz Though the lungs are predominantly affected in SARS-CoV-2-infected patients, extra-pulmonary manifestations can occur. Extra-pulmonary manifestations of the central and peripheral nervous system need to be recognised as they can strongly determine the outcome. This mini-review summarises and discusses previous and recent findings about neuro-COVID. The spectrum of central nervous system disease in COVID-19 patients is much broader than so far anticipated. Peripheral nerves and the skeletal muscle are less predominantly affected. In the vast majority of the cases, there is no direct attack of the virus towards vulnerable structures, which explains why various manifestations of the nervous system manifest favourably to immune suppression or immune modulation. Overall, the pathophysiology and clinical presentation of CNS/PNS involvement in COVID-19 is wider than believed. All patients with COVID-19 should be investigated by the neurologist for primary or secondary involvement of the CNS/PNS in the infection. neuro-COVID responds favourably to immune suppressants or immune modulation. Since the outbreak of the SARS-CoV-2 pandemic, it becomes increasingly evident that not only the lungs but also other organs may be directly or indirectly affected by the infection (extra-pulmonary involvement) [1] . Organs other than the lungs involved in the infection include the eyes, heart, kidneys, intestines, endocrine organs, skin, vessels, and the nervous system (neuro-COVID) [1 ] . This mini-review aims at summarising and discussing current knowledge about the clinical presentation and pathophysiology of neuro-COVID. Neurological disease in SARS-CoV-2-infected patients may not only be due to a direct viral attack towards neurons, glial cells, or components of cerebral vessels or the blood-brain barrier but also secondary due to the immune reaction against the virus, secondary to affection of the lungs, heart, or kidneys, or due to side effects of treatment applied during the acute infection. Additionally, pre-existing neurological disease may become clinically evident or worsen with COVID-19. Direct affection of the central nervous system (CNS) by the virus is rare and may cause meningitis/encephalitis [2, 3] , manifesting as headache, seizures, confusion, ataxia, pyramidal signs, or impaired consciousness ( Table 1) . Weakness of several studies on the neurological involvement in the infection is that most patients with clinical CNS manifestations did not undergo CNS imaging or investigations of the cerebrospinal fluid (CSF). In case patients undergo a spinal tap, the CSF is often not investigated for virus RNA or negative for the virus. If the CSF would be routinely investigated for virus RNA in COVID-19 patients, the virus would probably be more frequently detected in the CSF. Only with repeated spinal taps would it be possible to assess for how long the virus is present in the CNS after haematogenic or neuronal spread to ADEM acute disseminated encephalomyelitis, AHNE acute, haemorrhagic, necrotising encephalitis, CI cognitive impairment, HA headache, IC impaired consciousness, NMS neuroleptic malignant syndrome, nr not reported, PRES posterior, reversible encephalopathy syndrome, RL rhabdomyolysis, SD sensory disturbances the CNS. Direct affection of the peripheral nervous system (PNS) includes hyposmia or hypogeusia (Table 1) . Neurological disease due to the immune reaction (cytokine storm) against the virus includes myoclonus; acute disseminated encephalomyelitis (ADEM); acute, haemorrhagic, necrotising encephalopathy (AHNE) [6, 41] ; cerebral vasculitis; psychosis; delirium; transverse myelitis [7] ; cranial nerve palsy; Guillain-Barre syndrome (GBS) [42] ; mononeuritis; cytokine release syndrome (CRS) [8] ; or myositis [43] ( Table 1) . GBS is an increasingly recognised complication of COVID-19 and has been reported in at least 62 patients with COVID-19 [42] . Whether myositis in patients with COVID-19 is due to direct attack of the virus or secondary to the immune response remains speculative. In a recent case report about COVID-19 myositis, muscle biopsy showed inflammatory infiltration, but the virus was not found on electron microscopy [43] , suggesting that myositis is rather immune-mediated than infectious. A further argument for the immunogenic hypothesis of COVID-19 myositis provided a recent study on 20 patients with dermatomyositis showing that immunogenic epitopes attacked by autologous antiboides have high sequence identity to SARS-CoV-2 proteins [15] . Another neuro-immunologic complication of COVID-19 is transverse myelitis [42, 44] . Accordingly, in none of these patients was the CSF positive for virus RNA [42] . A recently described neuro-immunologic entity in COVID-19 is CRS, clinically manifesting with confusion, coma, tremor, cerebellar ataxia, behavioural alterations, aphasia, pyramidal signs, cranial nerve palsy, dysautonomia, and central hypothyroidism [8] . Another novel CNS complication of COVID-19 is myoclonus [10] , but it remains speculative if myoclonus is infectious, immune-mediated, post-hypoxic, or due to concomitant renal insufficiency [10] . Additionally, it has to be mentioned that CNS/PNS disease in COVID-19 may secondarily result from affection of the heart or the kidneys (Table 1) . Cardiac involvement may be responsible for cardioembolic, ischemic stroke, or ischemic stroke due to hypotension. Furthermore, CNS/PNS disease may be triggered by the anti-viral treatment or mechanical ventilation (Table 1) . Drugs used for the treatment of COVID-19 may induce toxic myopathy, critical ill myopathy, critical ill neuropathy, or rhabdomyolysis. Lastly, pre-existing CNS/PNS disease may deteriorate during the acute viral infection (Table 1) . Overall, the pathophysiology and clinical presentation of CNS/PNS involvement in COVID-19 is broader than usually anticipated. All patients with COVID-19 should be investigated by a neurologist for primary or secondary involvement of the CNS/PNS in the infection. Author Contribution JF: design, literature search, discussion, first draft, and critical comments. SF: literature search, critical comments, and final approval Data Availability All data are available from the corresponding author. Declarations We confirm adherence to ethical guidelines and indicate ethical approvals (IRB) and use of informed consent, as appropriate. Consent to Participate Not applicable. Conflict of Interest There authors declare no competing interests. Adherence to Instructions We confirm that the manuscript complies with all instructions to authors. COVID-19: staging of a new disease First case of 2019 novel coronavirus disease with encephalitis Meningococcal meningitis and COVID-19 co-infection A first case of acute cerebellitis associated with coronavirus disease (COVID-19): a case report and literature review Chemosensory dysfunction in COVID-19 out-patients COVID-19-associated acute necrotising encephalopathy successfully treated with steroids and polyvalent immunoglobulin with unusual IgG targeting the cerebral fibre network Transverse Myelitis in a Child With COVID-19 Cytokine release syndrome-associated encephalopathy in patients with COVID-19 Mixed central and peripheral nervous system disorders in severe SARS-CoV-2 infection Movement disorders as a new neurological clinical picture in severe SARS-CoV-2 infection Possible acute disseminated encephalomyelitis related to severe acute respiratory syndrome coronavirus 2 infection A case of possible atypical demyelinating event of the central nervous system following COVID-19 Immune-mediated neurological syndromes in SARS-CoV-2-infected patients Facial nerve palsy: an atypical clinical manifestation of COVID-19 infection in a family cluster Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis Rhabdomyolysis as an initial presentation in a patient diagnosed with COVID-19 Myasthenia gravis associated with SARS-CoV-2 infection [published online ahead of print Psychotic symptoms in COVID-19 patients. A retrospective descriptive study Prevalence and prognostic value of Delirium as the initial presentation of COVID-19 in the elderly with dementia: an Italian retrospective study Third cranial nerve palsy presenting with unilateral diplopia and strabismus in a 24-year-old woman with COVID-19 Unilateral hypoglossal nerve palsy as a Covid-19 sequel: a case report Cerebral nervous system vasculitis in a Covid-19 patient with pneumonia Critical illnessassociated cerebral microbleeds for patients with severe COVID-19: etiologic hypotheses COVID-19-associated encephalopathy with fulminant cerebral vasoconstriction: CT and MRI findings Panuveitis and optic neuritis as a possible initial presentation of the novel coronavirus disease 2019 (COVID-19) Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: a case report Multiple sclerosis following SARS-CoV-2 infection Anosmia and ageusia as the only indicators of coronavirus disease 2019 (COVID-19) Special considerations in the assessment of catastrophic brain injury and determination of brain death in patients with SARS-CoV-2 Posterior reversible encephalopathy syndrome (PRES): another imaging manifestation of COVID-19 Multiple acute ischemic strokes in a COVID-19 patient: a case report Intracranial hemorrhage in a young COVID-19 patient Extensive cerebral venous sinus thrombosis: a potential complication in a patient with COVID-19 disease Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: a retrospective cohort study Major neurologic adverse drug reactions, potential drug-drug interactions and pharmacokinetic aspects of drugs used in COVID-19 patients with stroke: a narrative review Neuroleptic malignant syndrome in a COVID-19 patient Clinical characteristics, diagnosis, and outcomes of 6 patients with COVID-19 infection and rhabdomyolysis Myasthenic syndrome caused by hydroxychloroquine used for COVID-19 prophylaxis COVID-19 and generalized myasthenia gravis exacerbation: a case report SARS-CoV-2-associated acute hemorrhagic, necrotizing encephalitis (AHNE) presenting with cognitive impairment in a 44-year-old woman without comorbidities: a case report SARS-CoV-2-associated Guillain-Barre syndrome in 62 patients COVID-19-associated myositis with severe proximal and bulbar weakness COVID-19-associated acute transverse myelitis: a rare entity Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations